The British Society for Antimicrobial Chemotherapy (BSAC) has urged other companies and major donors to boost coronavirus (COVID-19) research and development after pharmaceutical company Pfizer awarded $1million to its grants programme.
Access to quality-assured laboratory diagnosis has long been a challenge in low-income and middle-income countries (LMICs) resulting in delayed or inaccurate diagnosis and ineffective treatment. But innovative approaches to design are helping to reduce the cost and availability of life-saving equipment...
After careful consideration and extended discussions, BSAC Council has taken the decision to close our flagship Antimicrobial Resistance Surveillance Programme, and are inviting expressions of interest from academic or not-for-profit organisations who may be interested in adopting all/part of the isolate collection, which contains almost 100,000 isolates from a range of clinically significant species.
The British Society for Antimicrobial Chemotherapy (BSAC) has formally partnered with the European Bank for Reconstruction and Development (EBRD) in a bid to tackle antimicrobial resistance.
BSAC has responded to NHSE request for information on the deployment of OPAT services during COVID.
The BSAC Annual General Meeting will be held at 1300hrs on Thursday 28th May
NICE has published rapid guidance to Antibiotics for pneumonia in adults in hospital